复诺健生物科技有限公司于2015年创立于加拿大温哥华，并于2018年入驻上海南翔精准医学产业园建立临床转化中心。作为全球溶瘤病毒研发领域的创新者，复诺健依托其的Synerlytic™技术平台，通过表达多个协同性免疫调控因子，显著提高病毒溶瘤活性并大幅改善肿瘤微环境，从而有效地激活抗肿瘤免疫。
复诺健特有的转录翻译双重调控TTDR病毒骨架，进一步强化了病毒的安全性，从而突破了现有HSV溶瘤病毒只能瘤内注射的局限性，使得静脉注射成为可能，大大提升了临床操作的灵活性和便利性。
复诺健还与中国生物技术股份有限公司达成了长期战略合作关系，双方将共同成立合资公司，负责VG161在大中华区的临床推进和商业化。预计到2021年底，公司将启动上市计划，标的美国纳斯达克或香港证交所。
Virogin Biotech was founded in 2015, with a vision to be a global, best-in-class oncolytic virus company that creates impactful drugs for patients of highest medical need. We are a company with over 100 employees and R&D facilities in Vancouver, Canada and Shanghai, China.
At Virogin, we are at the forefront of developing novel oncolytic virotherapies. For every decision we make in the workplace, we think of the patients first. Virogin aims to be a Global, best-in-class oncolytic virus company that creates impactful drugs for patients of the highest medical need.
In 2019, Virogin and CNBG established a joint venture in Shanghai Nanxiang Biotech Campus. The entity is dedicated to clinical development, clinical operations, and manufacture deliveries for the global clinical market in North America, Australian, and China.
The company provides exciting and promising opportunities for experienced candidate and graduates. Scientific experts and business professionals, if you are highly motivated and passionate in curing cancers, improving human well-beings, sharing our mission of bring the best-in-class medicine to patients, please send us your application. Our Core Values are: Teamwork, Integrity, Creativity, Dedication, Reliability.
...
